| Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization D Planas, D Veyer, A Baidaliuk, I Staropoli, F Guivel-Benhassine, ... Nature 596 (7871), 276-280, 2021 | 2264 | 2021 |
| Considerable escape of SARS-CoV-2 Omicron to antibody neutralization D Planas, N Saunders, P Maes, F Guivel-Benhassine, C Planchais, ... Nature 602 (7898), 671-675, 2022 | 1532 | 2022 |
| Sensitivity of infectious SARS-CoV-2 B. 1.1. 7 and B. 1.351 variants to neutralizing antibodies D Planas, T Bruel, L Grzelak, F Guivel-Benhassine, I Staropoli, F Porrot, ... Nature medicine 27 (5), 917-924, 2021 | 778 | 2021 |
| Syncytia formation by SARS‐CoV‐2‐infected cells J Buchrieser, J Dufloo, M Hubert, B Monel, D Planas, MM Rajah, ... The EMBO journal 39 (23), e106267, 2020 | 521 | 2020 |
| Serum neutralization of SARS-CoV-2 Omicron sublineages BA. 1 and BA. 2 in patients receiving monoclonal antibodies T Bruel, J Hadjadj, P Maes, D Planas, A Seve, I Staropoli, ... Nature medicine 28 (6), 1297-1302, 2022 | 292 | 2022 |
| A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations L Grzelak, S Temmam, C Planchais, C Demeret, L Tondeur, C Huon, ... Science translational medicine 12 (559), eabc3103, 2020 | 278 | 2020 |
| Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection F Gallais, P Gantner, T Bruel, A Velay, D Planas, MJ Wendling, S Bayer, ... EBioMedicine 71, 2021 | 205 | 2021 |
| SARS‐CoV‐2 Alpha, Beta, and Delta variants display enhanced Spike‐mediated syncytia formation MM Rajah, M Hubert, E Bishop, N Saunders, R Robinot, L Grzelak, ... The EMBO journal 40 (24), e108944, 2021 | 192 | 2021 |
| Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers S Marot, I Malet, V Leducq, K Zafilaza, D Sterlin, D Planas, A Gothland, ... Nature communications 12 (1), 844, 2021 | 187 | 2021 |
| Resistance of Omicron subvariants BA. 2.75. 2, BA. 4.6, and BQ. 1.1 to neutralizing antibodies D Planas, T Bruel, I Staropoli, F Guivel-Benhassine, F Porrot, P Maes, ... Nature communications 14 (1), 824, 2023 | 172 | 2023 |
| HIV persists in CCR6+ CD4+ T cells from colon and blood during antiretroviral therapy A Gosselin, TRW Salinas, D Planas, VS Wacleche, Y Zhang, R Fromentin, ... Aids 31 (1), 35-48, 2017 | 161 | 2017 |
| Distinct evolution of SARS-CoV-2 Omicron XBB and BA. 2.86/JN. 1 lineages combining increased fitness and antibody evasion D Planas, I Staropoli, V Michel, F Lemoine, F Donati, M Prot, F Porrot, ... Nature Communications 15 (1), 2254, 2024 | 140 | 2024 |
| HIV-1 selectively targets gut-homing CCR6+ CD4+ T cells via mTOR-dependent mechanisms D Planas, Y Zhang, P Monteiro, JP Goulet, A Gosselin, N Grandvaux, ... JCI insight 2 (15), e93230, 2017 | 98 | 2017 |
| Identification of novel HIV-1 dependency factors in primary CCR4+CCR6+Th17 cells via a genome-wide transcriptional approach A Cleret-Buhot, Y Zhang, D Planas, JP Goulet, P Monteiro, A Gosselin, ... Retrovirology 12, 1-23, 2015 | 70 | 2015 |
| Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA. 2, BA. 4, and BA. 5 in patients receiving monoclonal antibodies T Bruel, K Stéfic, Y Nguyen, D Toniutti, I Staropoli, F Porrot, ... Cell Reports Medicine 3 (12), 2022 | 64 | 2022 |
| LILAC pilot study: effects of metformin on mTOR activation and HIV reservoir persistence during antiretroviral therapy D Planas, A Pagliuzza, R Ponte, A Fert, LR Marchand, M Massanella, ... EBioMedicine 65, 2021 | 59 | 2021 |
| A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients I Benotmane, T Bruel, D Planas, S Fafi-Kremer, O Schwartz, S Caillard Kidney international 101 (5), 1073-1076, 2022 | 56 | 2022 |
| HIV-1 is rarely detected in blood and colon myeloid cells during viral-suppressive antiretroviral therapy A Cattin, TRW Salinas, A Gosselin, D Planas, B Shacklett, EA Cohen, ... Aids 33 (8), 1293-1306, 2019 | 53 | 2019 |
| Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases J Hadjadj, D Planas, A Ouedrani, S Buffier, L Delage, Y Nguyen, T Bruel, ... Annals of the rheumatic diseases 81 (5), 720-728, 2022 | 52 | 2022 |
| Kinetics of the severe acute respiratory syndrome coronavirus 2 antibody response and serological estimation of time since infection S Pelleau, T Woudenberg, J Rosado, F Donnadieu, L Garcia, T Obadia, ... The Journal of infectious diseases 224 (9), 1489-1499, 2021 | 47 | 2021 |
